Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Aclaris Therapeutics, Inc. reported revenue of $8M, down 58.2% year over year. Operating margin was -975.9% and net margin -829.6%, on a free-cash-flow margin of -603.4% with capital expenditure at 1.4% of revenue. Every figure is computed directly from ACRS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $8M | -975.9% | -829.6% |
| FY2024 | $19M | -758.2% | -705.5% |
| FY2023 | $31M | -311.6% | -283.1% |
| FY2022 | $30M | -302.0% | -292.1% |
| FY2021 | $7M | -1327.1% | -1344.0% |
How does ACRS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.